4-M-E2 (4-Methoxyestradiol) and 4-OH-E2 (4-Hydroxyestradiol) are two important estrogen metabolites whose levels are of particular interest in post-menopausal women, especially when assessed through a Hormone and Urinary Metabolites Assessment Profile. This profile is designed to evaluate the balance and metabolism of hormones, providing valuable insights into a woman's health status after menopause.
In post-menopausal women, the production of estrogens like estradiol shifts from the ovaries to other tissues, and these changes can significantly impact the balance of estrogen metabolites. The ratios and levels of these metabolites can give clues about various health risks and conditions.
4-M-E2, known for its anti-angiogenic and potential anti-cancer properties, is a metabolite derived from the methoxylation of estradiol. Its levels can indicate how the body is processing and eliminating estrogens, which is crucial given that certain estrogen metabolites have been associated with an increased risk of hormone-related cancers.
4-OH-E2 is another metabolite of estradiol, formed through hydroxylation. This metabolite is often scrutinized because it can form reactive compounds that can damage DNA and potentially lead to cancerous changes. Therefore, monitoring its levels is particularly important for understanding cancer risk.
This assessment can be crucial for determining risks associated with hormone-related disorders, including breast cancer, osteoporosis, and cardiovascular diseases. It also aids in tailoring hormone replacement therapies, ensuring that they are safe and effective while mitigating potential risks associated with altered estrogen metabolism in the post-menopausal phase.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.